Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C: A pilot study

Katsuaki Tanaka; Masanori Ikeda; Akito Nozaki; Nobuyuki Kato; Hiroyuki Tsuda; Satoru Saito; Hisahiko Sekihara

doi:10.1111/j.1349-7006.1999.tb00756.x

Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C: A pilot study

Katsuaki Tanaka, Masanori Ikeda, Akito Nozaki, Nobuyuki Kato, Hiroyuki Tsuda, Satoru Saito, Hisahiko Sekihara

Research output: Contribution to journal › Article › peer-review

37 Citations (Scopus)

Abstract

Hepatitis C virus (HCV) is associated with the development of cirrhosis and hepatocellular carcinoma. We recently found that bovine lactoferrin, a milk protein belonging to the iron transporter family, effectively prevented HCV infection in cultured human hepatocytes (PH5CH8). We tested the hypothesis that lactoferrin inhibits HCV viremia in patients with chronic hepatitis C. Eleven patients with chronic hepatitis C received an 8-week course of bovine lactoferrin (1.8 or 3.6 g/day). At the end of lactoferrin treatment, a decrease in serum alanine transaminase and HCV RNA concentrations was apparent in 3 (75%) of 4 patients with low pretreatment serum concentrations of HCV RNA. However, 7 patients with high pretreatment concentrations showed no significant changes in these indices. This pilot study suggests that lactoferrin is one potential candidate as an anti-HCV reagent that may be effective for the treatment of patients with chronic hepatitis.

Original language	English
Pages (from-to)	367-371
Number of pages	5
Journal	Japanese Journal of Cancer Research
Volume	90
Issue number	4
DOIs	https://doi.org/10.1111/j.1349-7006.1999.tb00756.x
Publication status	Published - Apr 1999
Externally published	Yes

Keywords

Chronic hepatitis
Hepatitis C virus
Lactoferrin

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/j.1349-7006.1999.tb00756.x

Cite this

@article{03a3cd768ad7458486deaa5437fda3c8,

title = "Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C: A pilot study",

abstract = "Hepatitis C virus (HCV) is associated with the development of cirrhosis and hepatocellular carcinoma. We recently found that bovine lactoferrin, a milk protein belonging to the iron transporter family, effectively prevented HCV infection in cultured human hepatocytes (PH5CH8). We tested the hypothesis that lactoferrin inhibits HCV viremia in patients with chronic hepatitis C. Eleven patients with chronic hepatitis C received an 8-week course of bovine lactoferrin (1.8 or 3.6 g/day). At the end of lactoferrin treatment, a decrease in serum alanine transaminase and HCV RNA concentrations was apparent in 3 (75%) of 4 patients with low pretreatment serum concentrations of HCV RNA. However, 7 patients with high pretreatment concentrations showed no significant changes in these indices. This pilot study suggests that lactoferrin is one potential candidate as an anti-HCV reagent that may be effective for the treatment of patients with chronic hepatitis.",

keywords = "Chronic hepatitis, Hepatitis C virus, Lactoferrin",

author = "Katsuaki Tanaka and Masanori Ikeda and Akito Nozaki and Nobuyuki Kato and Hiroyuki Tsuda and Satoru Saito and Hisahiko Sekihara",

note = "Funding Information: The authors thank Kaisa Haatainen, Ph.D., and Tarja Saharinen, M.N.Sc., for their valuable contribution to the KUDEP study. SML was supported by Kuopio University Hospital EVO funding. HK-H was supported by the Academy of Finland (grant 116996 ).",

year = "1999",

month = apr,

doi = "10.1111/j.1349-7006.1999.tb00756.x",

language = "English",

volume = "90",

pages = "367--371",

journal = "Cancer Science",

issn = "1347-9032",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C

T2 - A pilot study

AU - Tanaka, Katsuaki

AU - Ikeda, Masanori

AU - Nozaki, Akito

AU - Kato, Nobuyuki

AU - Tsuda, Hiroyuki

AU - Saito, Satoru

AU - Sekihara, Hisahiko

N1 - Funding Information: The authors thank Kaisa Haatainen, Ph.D., and Tarja Saharinen, M.N.Sc., for their valuable contribution to the KUDEP study. SML was supported by Kuopio University Hospital EVO funding. HK-H was supported by the Academy of Finland (grant 116996 ).

PY - 1999/4

Y1 - 1999/4

N2 - Hepatitis C virus (HCV) is associated with the development of cirrhosis and hepatocellular carcinoma. We recently found that bovine lactoferrin, a milk protein belonging to the iron transporter family, effectively prevented HCV infection in cultured human hepatocytes (PH5CH8). We tested the hypothesis that lactoferrin inhibits HCV viremia in patients with chronic hepatitis C. Eleven patients with chronic hepatitis C received an 8-week course of bovine lactoferrin (1.8 or 3.6 g/day). At the end of lactoferrin treatment, a decrease in serum alanine transaminase and HCV RNA concentrations was apparent in 3 (75%) of 4 patients with low pretreatment serum concentrations of HCV RNA. However, 7 patients with high pretreatment concentrations showed no significant changes in these indices. This pilot study suggests that lactoferrin is one potential candidate as an anti-HCV reagent that may be effective for the treatment of patients with chronic hepatitis.

AB - Hepatitis C virus (HCV) is associated with the development of cirrhosis and hepatocellular carcinoma. We recently found that bovine lactoferrin, a milk protein belonging to the iron transporter family, effectively prevented HCV infection in cultured human hepatocytes (PH5CH8). We tested the hypothesis that lactoferrin inhibits HCV viremia in patients with chronic hepatitis C. Eleven patients with chronic hepatitis C received an 8-week course of bovine lactoferrin (1.8 or 3.6 g/day). At the end of lactoferrin treatment, a decrease in serum alanine transaminase and HCV RNA concentrations was apparent in 3 (75%) of 4 patients with low pretreatment serum concentrations of HCV RNA. However, 7 patients with high pretreatment concentrations showed no significant changes in these indices. This pilot study suggests that lactoferrin is one potential candidate as an anti-HCV reagent that may be effective for the treatment of patients with chronic hepatitis.

KW - Chronic hepatitis

KW - Hepatitis C virus

KW - Lactoferrin

UR - http://www.scopus.com/inward/record.url?scp=0032962172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032962172&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.1999.tb00756.x

DO - 10.1111/j.1349-7006.1999.tb00756.x

M3 - Article

C2 - 10363572

AN - SCOPUS:0032962172

SN - 1347-9032

VL - 90

SP - 367

EP - 371

JO - Cancer Science

JF - Cancer Science

IS - 4

ER -

Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C: A pilot study

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this